skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Fragment-Based and Structure-Guided Discovery and Optimization of Rho Kinase Inhibitors

Abstract

Using high concentration biochemical assays and fragment-based screening assisted by structure-guided design, we discovered a novel class of Rho-kinase inhibitors. Compound 18 was equipotent for ROCK1 (IC{sub 50} = 650 nM) and ROCK2 (IC{sub 50} = 670 nM), whereas compound 24 was more selective for ROCK2 (IC{sub 50} = 100 nM) over ROCK1 (IC{sub 50} = 1690 nM). The crystal structure of the compound 18-ROCK1 complex revealed that 18 is a type 1 inhibitor that binds the hinge region in the ATP binding site. Compounds 18 and 24 inhibited potently the phosphorylation of the ROCK substrate MLC2 in intact human breast cancer cells.

Authors:
; ; ; ; ; ; ; ; ; ; ; ; ; ;  [1]
  1. (Moffitt)
Publication Date:
Research Org.:
Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
Sponsoring Org.:
OTHER
OSTI Identifier:
1038274
Resource Type:
Journal Article
Resource Relation:
Journal Name: J. Med. Chem.; Journal Volume: 55; Journal Issue: (5) ; 03, 2012
Country of Publication:
United States
Language:
ENGLISH
Subject:
59 BASIC BIOLOGICAL SCIENCES; 60 APPLIED LIFE SCIENCES; CRYSTAL STRUCTURE; DESIGN; MAMMARY GLANDS; NEOPLASMS; OPTIMIZATION; PHOSPHORYLATION; PHOSPHOTRANSFERASES; SUBSTRATES

Citation Formats

Li, Rongshi, Martin, Mathew P., Liu, Yan, Wang, Binglin, Patel, Ronil A., Zhu, Jin-Yi, Sun, Nan, Pireddu, Roberta, Lawrence, Nicholas J., Li, Jiannong, Haura, Eric B., Sung, Shen-Shu, Guida, Wayne C., Schonbrunn, Ernst, and Sebti, Said M. Fragment-Based and Structure-Guided Discovery and Optimization of Rho Kinase Inhibitors. United States: N. p., 2012. Web. doi:10.1021/jm201289r.
Li, Rongshi, Martin, Mathew P., Liu, Yan, Wang, Binglin, Patel, Ronil A., Zhu, Jin-Yi, Sun, Nan, Pireddu, Roberta, Lawrence, Nicholas J., Li, Jiannong, Haura, Eric B., Sung, Shen-Shu, Guida, Wayne C., Schonbrunn, Ernst, & Sebti, Said M. Fragment-Based and Structure-Guided Discovery and Optimization of Rho Kinase Inhibitors. United States. doi:10.1021/jm201289r.
Li, Rongshi, Martin, Mathew P., Liu, Yan, Wang, Binglin, Patel, Ronil A., Zhu, Jin-Yi, Sun, Nan, Pireddu, Roberta, Lawrence, Nicholas J., Li, Jiannong, Haura, Eric B., Sung, Shen-Shu, Guida, Wayne C., Schonbrunn, Ernst, and Sebti, Said M. Mon . "Fragment-Based and Structure-Guided Discovery and Optimization of Rho Kinase Inhibitors". United States. doi:10.1021/jm201289r.
@article{osti_1038274,
title = {Fragment-Based and Structure-Guided Discovery and Optimization of Rho Kinase Inhibitors},
author = {Li, Rongshi and Martin, Mathew P. and Liu, Yan and Wang, Binglin and Patel, Ronil A. and Zhu, Jin-Yi and Sun, Nan and Pireddu, Roberta and Lawrence, Nicholas J. and Li, Jiannong and Haura, Eric B. and Sung, Shen-Shu and Guida, Wayne C. and Schonbrunn, Ernst and Sebti, Said M.},
abstractNote = {Using high concentration biochemical assays and fragment-based screening assisted by structure-guided design, we discovered a novel class of Rho-kinase inhibitors. Compound 18 was equipotent for ROCK1 (IC{sub 50} = 650 nM) and ROCK2 (IC{sub 50} = 670 nM), whereas compound 24 was more selective for ROCK2 (IC{sub 50} = 100 nM) over ROCK1 (IC{sub 50} = 1690 nM). The crystal structure of the compound 18-ROCK1 complex revealed that 18 is a type 1 inhibitor that binds the hinge region in the ATP binding site. Compounds 18 and 24 inhibited potently the phosphorylation of the ROCK substrate MLC2 in intact human breast cancer cells.},
doi = {10.1021/jm201289r},
journal = {J. Med. Chem.},
number = (5) ; 03, 2012,
volume = 55,
place = {United States},
year = {Mon May 14 00:00:00 EDT 2012},
month = {Mon May 14 00:00:00 EDT 2012}
}